HODO-2224-1

· Hyundai Pharm

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HODO-2224-1, covering 2025-05-22 to 2025-05-22. Get the full timeline:

Most recent: Clinical Trial Update: To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia [Phase 3]

See pricing